News
Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...
From drug trials to mechanistic insights, EULAR 2025 delivers wide-ranging data that may inform tomorrow’s standards in ...
EULAR 2025 Meeting Target Serum Urate Level Cuts CV Risk in Gout Gout patients who met a target serum urate level of 360 μmol/L (6 mg/dL) within 12 months of treatment cut their risk for major ...
Vaccination Tied to Better Survival in COVID-Linked AKI Patients hospitalized with COVID-linked acute kidney injury are more likely to survive if they are vaccinated than if they are not, a recent ...
Statin-induced myopathy is a well-known adverse effect. Recently, short-term administration of statins has been shown to decrease cardiorespiratory fitness through inducing mitochondrial damage. [5] ...
Carrie S Oliphant; Justin McCullough; Taimoor Hashim and Rami N Khouzam Disclosures Future Cardiol. 2014;10 (2):229-233.
Myopathy can be divided into three categories: myalgias, myositis and rhabdomyolysis. Myalgias are described as a soreness, tenderness or weakness of muscles, either at rest or brought on by exertion.
The major adverse effect of statins is the potential for liver and muscle toxicity. All statins can cause hepatotoxicity or myopathy. Hepatotoxicity is defined as an elevation in liver transaminases ...
This treatment was associated with a reversible toxic mitochondrial myopathy that resembled polymyositis. [34] Affected patients presented with myalgia, muscle tenderness and proximal muscle weakness.
Acute myopathy in ICU patients is also reported after administration of the benzylisoquinolinium NMBAs (i.e., atracurium, cisatracurium, doxacurium). [24, 34, 69] Common to all these reports is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results